Open in interactive viewer → charts, metric popovers & call review

Hyperfine's Best Quarter Ever Lands on a Stock Cut in Half

Record revenue, first revenue-above-burn milestone, and a fresh pivot to 'brain wellness' — yet the tape has spent 90 days voting no
HYPR · Earnings Call · 2026-11-09

A quarter that finally looks like a business

Hyperfine's third quarter of 2026 was, by its own accounting, the best in company history: revenue of $6.0 million, up 53% sequentially and 73% year-over-year, gross margin of 56.7%, and net cash burn down to $5.6 million — the first time quarterly revenue exceeded quarterly cash burn. Maria Sainz did not hedge: “This is not just a great quarter, it marks the beginning of a new trajectory.” — Maria Sainz, Chief Executive Officer or Senior Executive (likely CEO) · 2026-11-09 Brett Hale framed the leverage crisply: “Revenue increased 53% sequentially, while operating expenses increased less than 2%.” — Brett Hale, Chief Administrative Officer and Chief Financial Officer · 2026-11-09 That is not a promotional flourish; it is arithmetic. The company added $1.4 million of gross profit against $0.2 million of incremental operating expense quarter-over-quarter, and the operating loss narrowed to its smallest ever at $7.3 million. The reported fundamentals confirm the trend rather than just the pitch. Gross margin has climbed from roughly 29% in mid-2022 to above 50% for five consecutive quarters, and free cash flow losses have compressed from double-digit millions toward the mid-single digits. Unit mix and a record average selling price — a high average selling price the company has now pushed twice on Model 2 — did the heavy lifting.

The divergence is the story

Here is the tension that defines this print. Over the last 90 trading days HYPR fell 44%, sliding from a July peak near $1.22 straight into the report. A record quarter is landing into a stock that was already cut nearly in half going in. The price-to-revenue multiple sits near 8.7x trailing, down more than 90% from the nosebleed levels of the SPAC era but still not obviously discounted against a $20–22 million revenue base. The market's skepticism is not irrational — it is a bet on whether this is a durable trajectory or a lumpy capital-equipment quarter dressed up. And management quietly fed that skepticism on guidance. Revenue is a record, yet the full-year range was reaffirmed, not raised, at $20–22 million. When Frank Takkinen pressed on why not lift it, Hale offered: “We felt good that the $20 million to $22 million was still a good landing zone given the business, the opportunities and the visibility.” — Brett Hale, Chief Administrative Officer and Chief Financial Officer · 2026-11-09 Sainz added the caveat that last year's Q4 carried a onetime multi-unit upgrade. Read plainly: the quarter was excellent, but the business is not yet linear enough to promise a step-up.

The pivot nobody has priced

The genuinely new material this quarter was strategic, not financial. Sainz recast the entire company away from the medical-device frame:

Hyperfine is transforming from our origins as a highly innovative niche medical technology company to our present and future as a broad-based medical and wellness platform with a vision to improve brain health globally.

Maria Sainz, Chief Executive Officer or Senior Executive (likely CEO) · 2026-11-09
That shows up in the keyword record as a cluster of brand-new themes: wellness, longevity, concierge practice, and brain health all surfaced high in the Q3 keyword set where they did not exist in prior calls. The pitch is that accessible brain MRI can serve memory clinics and concierge practices where imaging becomes a consumer experience, and that the Swoop hardware is the platform the AI imaging ecosystem needs to scale. But the same CEO who painted the vision told Alex Nowak not to pay for it yet: “I wouldn't really bank on anything translating into actual revenue into '27, but more into '28 and beyond.” — Maria Sainz, Chief Executive Officer or Senior Executive (likely CEO) · 2026-11-09 That is the honest shape of a story stock — a large optionality narrative bolted onto a company that still has to sell $590,000 capital units one health system at a time. It also explains why the tape may be discounting it: wellness revenue is, by management's own admission, years out.

What management stopped saying

The subtle tell is on the other side of the ledger. Even as the company published the NEURO PMR study and completed contrast enrollment, the keywords most sharply de-emphasized in this transcript were clinical evidence and clinical utility. The narrative hand-off is real: the burden of proof is shifting from peer-reviewed clinical utility toward a consumer-wellness promise. For a company whose product must win hospital procurement committees on ROI, that is worth watching closely. Meanwhile the older, more concrete story is not new at all — and that is reassuring. The health systems land-and-expand motion was already pitched a year ago; in May, Sainz described an IDN “that has moved from the first to multiple in 1 site to a second site and to a third site.” — Maria Sainz, Chief Administrative Officer · 2026-05-12 The difference now is that health systems have become the single loudest revenue driver, not a talking point. The contrast indication thesis is similarly seasoned: back in May, Sainz said “I cannot think of any case in a hospital environment where the purchase has been put on hold awaiting contrast.” — Maria Sainz, Chief Administrative Officer · 2026-05-12 Now the 510(k) is pledged by year-end 2026 with a read-through to a mid-2027 clearance — the catalyst, if it comes, is a well-telegraphed one.

What actually matters from here

Three things separate a re-rating from another leg down. First, the contrast 510(k) — a real tailwind for the office and operating-room use cases and a re-activator of prospective office customers that failed the ROI test without it. Second, the first full capital-planning cycle since Model 2, which management believes converts health-system pipelines that today are "not now" rather than "no." Third, the cash story: $37.9 million on the balance sheet plus up to $25 million of undrawn debt capacity and a reaffirmed runway into 2028 buys time to prove the trajectory. The bull case here is simple: a sub-$70 million market-cap company where revenue just crossed cash burn, gross margin is structurally above 50%, and the operating plan no longer requires equity. The bear case is equally simple: a stock that has fallen 44% in 90 days on a quarter that beat, because the company declined to raise guidance and its newest growth story does not generate revenue until 2028. This is a name in motion — but the motion, for now, is the market's skepticism against management's insistence that this is 'the new Hyperfine.'